Emerging CAR T-Cell Therapies in Hematologic Cancers

Video

Xiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.

Xiuli Wang, PhD, research professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, discusses emerging CAR T-cell therapy in hematologic cancers.

Currently available CAR T-cell therapies, although very promising for blood cancers like leukemia and lymphoma, has many challenges, explains Wang. Not all patients respond to CAR T-cell therapy; others might respond but relapse soon after. The reason for these challenges, according to Wang, is that there are not enough CAR T cells in patients.

These newer CAR T cells, which Wang is studying at the City of Hope Comprehensive Cancer Center, allow physicians to expand CAR T cells in patients by using cytomegalovirus (CMV) vaccines. With this new technology, these CAR molecules are introduced into the CMV-specific T cells, allowing the resulting T cells to have 2 specificities; they can recognize tumor and CMV antigens, concludes Wang.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.